Regorafénib N-oxyde (M2)-13C,d3

Modify Date: 2024-01-11 17:41:31

Regorafénib N-oxyde (M2)-13C,d3 structure	Common Name	Regorafénib N-oxyde (M2)-13C,d3
	CAS Number	2140317-01-5	Molecular Weight	502.83
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₀₁₃CH₁₂D₃ClF₄N₄O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Regorafénib N-oxyde (M2)-13C,d3

Regorafénib N-oxyde (M2)-13C,d3 is the 13C- and deuterium labeled. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Name	Regorafénib N-oxyde (M2)-13C,d3

Description	Regorafénib N-oxyde (M2)-13C,d3 is the 13C- and deuterium labeled. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
Related Catalog	Research Areas >> Cancer
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[90].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48.

Molecular Formula	C₂₀₁₃CH₁₂D₃ClF₄N₄O₄
Molecular Weight	502.83

Regorafénib N-oxyde (M2)-13C,d3

Use of Regorafénib N-oxyde (M2)-13C,d3

Names

Regorafénib N-oxyde (M2)-13C,d3 Biological Activity

Chemical & Physical Properties